GlassScriptPhysician profile
Lindsay Lee
NPI 1366948556
$3,882.59
in general payments reported to CMS, 2019-2025
39 companies · $555 in 2025
The $555 reported for 2025 was more than what 77% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $1,120 · 2023: $1,153 · 2024: $774 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.00 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $714.60 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $666.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $262.90 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $200.48 | 2022-2023 | |
| Dexcom, INC. | $195.37 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.93 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $142.33 | 2021-2023 | Prolia, Evenity, Repatha |
| Stemline Therapeutics INC. | $135.74 | 2023 | Orserdu |
| Astellas Pharma US INC | $129.64 | 2022-2025 | Veozah |
| Pfizer INC. | $125.39 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $120.72 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.84 | 2022-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $85.38 | 2023-2024 | Rexulti, Nuedexta |
| Xeris Pharmaceuticals, INC. | $67.07 | 2021-2023 | Gvoke Hypopen |
| Antares Pharma, INC. | $66.66 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $64.64 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $54.26 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $48.88 | 2022-2023 | Shingrix, Bexsero |
| Daiichi Sankyo INC. | $48.09 | 2022 | |
| Mannkind Corporation | $47.98 | 2021-2023 | Afrezza |
| Merck Sharp & Dohme LLC | $41.43 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $33.80 | 2021 | |
| Cequr Corporation | $31.73 | 2022 | |
| Radius Health, INC. | $29.77 | 2022-2023 | Tymlos |
| Abbott Laboratories | $29.22 | 2021-2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $28.50 | 2025 | Camzyos, Eliquis |
| Tolmar, INC. | $28.48 | 2024-2025 | Jatenzo |
| Biohaven Pharmaceutical Holding Company LTD. | $27.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.60 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $20.00 | 2025 | Neffy |
| Irhythm Technologies, INC. | $18.58 | 2024 | Zio Xt Patch, Zio Monitor |
| Corcept Therapeutics | $18.57 | 2024 | Korlym |
| Sumitomo Pharma America, INC. | $18.43 | 2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $16.73 | 2023 | |
| Madrigal Pharmaceuticals | $16.13 | 2024 | Resmetirom |
| Biohaven Pharmaceuticals, INC. | $15.03 | 2021 | |
| Shield Therapeutics INC | $14.71 | 2024 | |
| Medtronic, INC. | $13.75 | 2022 | |
| Eisai INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.